Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa ABX464 50 mg once daily versus placebo in moderate to severe ulcerative colitis
2017-000937-30Phase 2Completed
- Sponsor
- Abivax
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing ABX464 50 mg once daily with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Aug 2017; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-000937-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000937-30.